News & Events

News


Thursday April 08, 2021

Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting

SAN DIEGO , April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences , Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.


Thursday March 25, 2021

Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day

SAN DIEGO , March 25, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3 rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021 . Eiry Roberts, Chief Medical Officer, and Kyle Gano , Chief Business Development and Strategy Officer, will


Saturday March 20, 2021

Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021

- Additional Positive Data from Phase II CAHlibrate Study - Real-World Data Highlight Impact of CAH in Adult and Pediatric Patients SAN DIEGO , March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II


Tuesday March 09, 2021

Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN DIEGO , March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31 st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021 . Matt Abernethy , Chief Financial Officer, will present at the conference.


Tuesday March 02, 2021

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

- Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS) - Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat - No New

Events